ReviewCurrent oncology (Toronto, Ont.)2018
Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review.
Review in Current oncology (Toronto, Ont.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Paraneoplastic Neurological Syndromes Associated with Ovarian Tumors: A Case Report and Systematic Review.Diagnostics (Basel, Switzerland) · 2026Article
- Movement Disorders Associated With Breast Cancer: A Systematic Review.Annals of Indian Academy of Neurology · 2026Article
- Paraneoplastic cerebellar degeneration from an isolated nodal clear cell carcinoma of suspected gynecologic origin: case report and literature review.Journal of cancer research and clinical oncology · 2026Review
- Breast Cancer with Subacute Progressive Neurological Symptoms due to Anti-Yo Antibody-Associated Paraneoplastic Neurological Syndrome: A Case Report.Surgical case reports · 2026Article
- Article
- Case report: anti-IgLON5 disease combined with paraneoplastic cerebellar degeneration with the detection of anti-sulfatide IgG antibody, masquerading as meningoencephalitis.BMC neurology · 2024Article
- Autoimmune Encephalitis: Insights Into Immune-Mediated Central Nervous System Injury.Korean journal of radiology · 2024Review
- Significant improvement in paraneoplastic neurological syndromes without identifiable anti-neural antibodies in patients with breast cancer after breast surgery.International cancer conference journal · 2024Article
- Overview of Paraneoplastic Autoantibody-Mediated Cognitive Impairment and Behavioral Changes: A Narrative Review.Cureus · 2024Review
- Paraneoplastic neurological syndromes of the central nervous system: a single institution 7-year case series.Acta neurologica Belgica · 2023Article
- Antineuronal autoantibodies induced paraneoplasic syndrome in schizophrenia spectrum disorders: case report.Annals of medicine and surgery (2012) · 2023Article
- Maternal brain reactive antibodies profile in autism spectrum disorder: an update.Translational psychiatry · 2023Review
- Rapid-onset paraneoplastic cerebellar degeneration successfully treated by radiotherapy and tumorectomy.International cancer conference journal · 2023Article
- Autoimmune Encephalitis: A Physician's Guide to the Clinical Spectrum Diagnosis and Management.Brain sciences · 2022Review
- The early diagnoses and treatment of anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a patient with breast cancer: a case report.Translational cancer research · 2022Article
- Case report: Acute vestibular syndrome and cerebellitis in anti-Yo paraneoplastic syndrome.Frontiers in neurology · 2022Article
- Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature.Cureus · 2021Article
- Paraneoplastic Encephalitis Associated with Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.Journal of breast cancer · 2021Article
- A Rare Coexistence of Paraneoplastic Cerebellar Degeneration: Papillary Thyroid Carcinoma.Current oncology (Toronto, Ont.) · 2021Article
- Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome.Journal of clinical neurology (Seoul, Korea) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common cancer in women, with 15%-25% of those tumours overexpressing the human epidermal growth factor receptor 2 (her2), which is associated with more aggressive disease. On rare occasions, patients present with a paraneoplastic syndrome months to years before their cancer diagnosis. Paraneoplastic cerebellar degeneration (pcd) is associated with fewer than 1% of cancers and is strongly associated with breast and gynecologic malignancies. Anti-Yo antibody is the antibody most frequently identified with the syndrome, and it is associated with a very poor prognosis. Recent studies have implicated a relationship between overexpression of her2 and anti-Yo-mediated pcd. Current pcd treatments include tumour removal, chemotherapy, targeted therapy, and immune-suppressive treatments. Outcomes of pcd are typically poor, and no guidelines for treatment currently exist. Early recognition followed by rapid initiation of treatment remains the cornerstone of therapy. Here, we present a case of anti-Yo-antibody pcd secondary to estrogen and progesterone receptor-negative, her2-positive breast cancer. Despite treatment with mastectomy, chemotherapy, and her2-targeted therapy, no significant neurologic improvement was achieved, and cerebellar cognitive affective syndrome subsequently developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.